| 4/27/22 |
Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D Day |
| 4/21/22 |
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2022 Financial Results on May 5, 2022 |
| 4/13/22 |
Vir Biotechnology to Host a Virtual Hepatitis Portfolio R&D Day |
| 4/6/22 |
Vir Biotechnology Scientists Named Winners of the BARDA and HHS-Sponsored Pediatric COVID-19 Data Challenge |
| 4/4/22 |
Vir Biotechnology to Participate in the 21st Annual Needham Healthcare Conference |
| 3/25/22 |
US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA.2 Subvariant |
| 3/2/22 |
Vir Biotechnology to Participate in the 42nd Annual Cowen Healthcare Conference |
| 2/24/22 |
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results |
| 2/10/22 |
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022 |
| 2/10/22 |
Data Suggest Sotrovimab Retains Neutralizing Activity Against Omicron Subvariant BA.2 |
